Mr. George Reznik reports

LIGHT AI ANNOUNCES BUSINESS UPDATE

Light AI Inc. has provided a Q1 progress update regarding its artificial intelligence (AI) health and wellness initiatives.

"We are excited to share an update on the remarkable progress made by Light AI with our mature algorithm. The performance has exceeded expectations, and we are now expediting the process of optimizing its integration into both the professional and wellness markets," stated Peter Whitehead, chief executive officer of Light AI. "Our dedicated team has been working tirelessly to ensure that the algorithm's capabilities are fully harnessed to deliver exceptional value across these sectors. We are positioned to seize new market opportunities and expand our offering through incremental health solutions. These advancements not only strengthen our market position while expanding commercialization opportunities. We are confident that our ongoing improvements will deliver innovation, further solidifying our leadership in the market."

Product validation

Reliability, scalability, security and quality remain essential attributes to ensure trust and integrity in the company's offerings. The company has engaged Emergo to assist in the formation of a robust quality management process with regulatory considerations to satisfy the health care professional requirements for the Canadian, the United States and African markets.

Clinical trial in Africa

The company's regulatory team has successfully developed and optimized a comprehensive regulatory and clinical trial strategy. This pathway is expected to significantly accelerate its rollout across Africa. By streamlining the company's regulatory and clinical processes, it anticipates an optimized approval timeline, enabling acceleration of its innovative solutions to the African market. This strategic advancement is anticipated to accelerate the company's market penetration as it enables delivery to a global audience. Light AI's go-to-market path for lower-and-middle-income countries (LMIC) initially targeted launching its AI (artificial intelligence) health and wellness applications in up to 20 African countries over a three-year period. The company anticipates that this time frame has been significantly accelerated.

About Light AI Inc.

Light AI is a health care company focused on developing artificial intelligence health diagnostic applications. Light AI is developing a technology platform that represents the next generation of patient management: It applies AI algorithms to smart phone images -- starting with images of streptococcus A -- to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind; its hardware platform is the 4.5 billion smart phones that exist in the world today.

In pre-FDA (U.S. Food and Drug Administration) validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A streptococcus (GAS). The company's algorithm-generated pre-FDA results were in the range of the gold-standard swab culture currently used for diagnosing GAS, achieving a 96.57-per-cent accuracy rate and a negative predictive value (NPV) of 100 per cent, indicating its high reliability in confirming the absence of streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as rheumatic heart disease (RHD), which imposes a global economic burden exceeding $1-trillion annually. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smart phone images can be expanded to other throat conditions as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smart phone with AI in the cloud to create a digital clinical lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

We seek Safe Harbor.